Novo Nordisk Buy Recommendation Post Earnings

about 1 month ago

Parkev Tatevosian, CFA

"But still, even after adjusting the risk higher, the intrinsic value per share is meaningfully higher than the company's market price. It's trading at $46 a share. And the intrinsic value I calculated is $116. So even after all of these difficulties, I still feel this stock is a good risk versus reward for long-term investors. Given the significant headwinds from pricing pressures and competitive challenges, I believe the upside remains compelling."

The analyst updates his recommendation on Novo Nordisk post-earnings by highlighting that, despite competitive and regulatory pressures affecting its weight loss treatments, the company's intrinsic value of $116 per share far exceeds its current trading price of around $46. He maintains a buy rating, believing that the long-term risk versus reward remains favorable.

Related Stocks